NuVasive, Inc, a medical device company, develops and markets minimally disruptive surgical products and procedurally integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal products include Maximum Access Surgery, a minimally disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Phone858-909-1800
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.10 billion
Profitability
Miscellaneous
Employees2,600
Next Earnings Date10/29/2019 (Estimated)
OptionableOptionable
NuVasive (NASDAQ:NUVA) Frequently Asked Questions
What is NuVasive's stock symbol?
NuVasive trades on the NASDAQ under the ticker symbol "NUVA."
How will NuVasive's stock buyback program work?
NuVasive announced that its board has authorized a share buyback plan on Wednesday, October 25th 2017, which permits the company to buyback $100,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to reacquire shares of its stock through open market purchases. Stock buyback plans are typically a sign that the company's leadership believes its stock is undervalued.
How were NuVasive's earnings last quarter?
NuVasive, Inc. (NASDAQ:NUVA) announced its quarterly earnings data on Tuesday, July, 30th. The medical device company reported $0.63 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.56 by $0.07. The medical device company earned $292.11 million during the quarter, compared to analyst estimates of $290.59 million. NuVasive had a net margin of 4.65% and a return on equity of 15.09%. The company's revenue was up 3.7% on a year-over-year basis. During the same period in the prior year, the business posted $0.58 EPS. View NuVasive's Earnings History.
When is NuVasive's next earnings date?
What guidance has NuVasive issued on next quarter's earnings?
NuVasive updated its FY19 earnings guidance on Tuesday, July, 30th. The company provided EPS guidance of $2.25-2.35 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.28. The company issued revenue guidance of $1.14-1.16 billion, compared to the consensus revenue estimate of $1.15 billion.
What price target have analysts set for NUVA?
13 brokers have issued twelve-month price objectives for NuVasive's stock. Their predictions range from $55.00 to $75.00. On average, they expect NuVasive's stock price to reach $68.08 in the next twelve months. This suggests a possible upside of 7.0% from the stock's current price. View Analyst Price Targets for NuVasive.
What is the consensus analysts' recommendation for NuVasive?
13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NuVasive in the last year. There are currently 1 sell rating, 6 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for NuVasive.
What are Wall Street analysts saying about NuVasive stock?
Here are some recent quotes from research analysts about NuVasive stock:
- 1. According to Zacks Investment Research, "NuVasive witnessed balanced revenue growth across all of its key operating segments. Robust sales in the international markets buoy optimism. We are also upbeat about the company having witnessed sturdy demand across an array of recent products launches within the U.S. Spinal Hardware business viz. the TLX 20 Degree expandable cage. On the flip side, the Biologics business performance was disappointing. Headwinds like pricing pressure, reimbursement issues and a competitive landscape are major downsides for NuVasive. In the past six months, NuVasive has outperformed its industry. " (7/10/2019)
- 2. Cantor Fitzgerald analysts commented, ": We maintain our Neutral rating on NUVA, but raise our 12- month PT to $61 from $50 as NUVA’s performance justifies multiple expansion. NUVA reported 1Q revenue of $274.8MM (+5.9% organic), beating FactSet consensus by $5.6MM. 40bp benefit from one-time NCS collections and a faster-than-expected benefit from West Carrollton, GM (72.9%) and OM (14.9%) were higher than expectations, driving an EPS beat of $0.12. A number of favorable one-time items make determining the true underlying performance challenging." (5/2/2019)
Has NuVasive been receiving favorable news coverage?
Media coverage about NUVA stock has trended positive recently, InfoTrie reports. The research group scores the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. NuVasive earned a news sentiment score of 2.7 on InfoTrie's scale. They also assigned headlines about the medical device company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for NuVasive.
Who are some of NuVasive's key competitors?
Some companies that are related to NuVasive include Insulet (PODD), ABIOMED (ABMD), Novocure (NVCR), Hill-Rom (HRC), Haemonetics (HAE), Integra Lifesciences (IART), Penumbra (PEN), Globus Medical (GMED), Tandem Diabetes Care (TNDM), ICU Medical (ICUI), Cantel Medical (CMD), Nevro (NVRO), Glaukos (GKOS), Irhythm Technologies (IRTC) and Cardiovascular Systems (CSII).
What other stocks do shareholders of NuVasive own?
Who are NuVasive's key executives?
NuVasive's management team includes the folowing people:
- Mr. J. Christopher Barry, CEO & Director (Age 46)
- Mr. Matthew W. Link, Pres (Age 44)
- Dr. Peter M. Leddy, Exec. VP of People & Culture (Age 56)
- Mr. Rajesh J. Asarpota, Exec. VP & CFO (Age 52)
- Mr. Jereme Sylvain, Chief Accounting Officer (Age 39)
Who are NuVasive's major shareholders?
NuVasive's stock is owned by many different of institutional and retail investors. Top institutional investors include Copper Rock Capital Partners LLC (0.43%), Pacer Advisors Inc. (0.04%), State of Alaska Department of Revenue (0.02%), Cerebellum GP LLC (0.01%), Fox Run Management L.L.C. (0.01%) and Diversified Trust Co (0.01%). Company insiders that own NuVasive stock include Gregory T Lucier and Matthew Link. View Institutional Ownership Trends for NuVasive.
Which institutional investors are selling NuVasive stock?
Which institutional investors are buying NuVasive stock?
NUVA stock was purchased by a variety of institutional investors in the last quarter, including Copper Rock Capital Partners LLC, State of Alaska Department of Revenue and Fox Run Management L.L.C.. View Insider Buying and Selling for NuVasive.
How do I buy shares of NuVasive?
Shares of NUVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is NuVasive's stock price today?
One share of NUVA stock can currently be purchased for approximately $63.63.
How big of a company is NuVasive?
NuVasive has a market capitalization of $3.31 billion and generates $1.10 billion in revenue each year. The medical device company earns $12.47 million in net income (profit) each year or $2.23 on an earnings per share basis. NuVasive employs 2,600 workers across the globe.View Additional Information About NuVasive.
What is NuVasive's official website?
How can I contact NuVasive?
NuVasive's mailing address is 7475 LUSK BOULEVARD, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-909-1800 or via email at [email protected]
MarketBeat Community Rating for NuVasive (NASDAQ NUVA)
MarketBeat's community ratings are surveys of what our community members think about NuVasive and other stocks. Vote "Outperform" if you believe NUVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NUVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
